Patents by Inventor Stephen Ullrich
Stephen Ullrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7964190Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.Type: GrantFiled: February 28, 2003Date of Patent: June 21, 2011Assignee: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Guo-Liang Yu, Steven M Ruben, Yifan Zhai, Stephen Ullrich
-
Publication number: 20100261207Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: March 30, 2007Publication date: October 14, 2010Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich, Marc Chevrier
-
Publication number: 20100196360Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: September 12, 2008Publication date: August 5, 2010Applicant: Human Genome Sciences, Inc.Inventors: GUO-LIANG YU, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich
-
Publication number: 20090221008Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: March 30, 2007Publication date: September 3, 2009Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich, Marc Chevrier
-
Publication number: 20090104189Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: September 12, 2008Publication date: April 23, 2009Applicant: Human Genome Sciences, Inc.Inventors: GUO-LIANG YU, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich
-
Publication number: 20050186637Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: February 10, 2005Publication date: August 25, 2005Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig Rosen, Stephen Ullrich
-
Publication number: 20040009147Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.Type: ApplicationFiled: February 28, 2003Publication date: January 15, 2004Applicant: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Yifan Zhai, Stephen Ullrich
-
Patent number: 6635743Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.Type: GrantFiled: March 10, 2000Date of Patent: October 21, 2003Assignee: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Stephen Ullrich, Yifan Zhai
-
Publication number: 20030175208Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: October 16, 2002Publication date: September 18, 2003Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich, Michael Laird
-
Publication number: 20030143696Abstract: The present invention relates to a novel CK&bgr;-13 protein which is a member of the chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK&bgr;-13 protein. CK&bgr;-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK&bgr;-13 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: ApplicationFiled: November 1, 2002Publication date: July 31, 2003Applicant: Human Genome Sciences, Inc.Inventors: Haodong Li, George Seibel, Stephen Ullrich, Francis W. Luscinskas
-
Patent number: 6495520Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.Type: GrantFiled: February 19, 1999Date of Patent: December 17, 2002Assignee: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jun Zhang, Stephen Ullrich, Yifan Zhai
-
Publication number: 20020187526Abstract: The present invention relates to Neutrokine-alpha binding polypeptides (NAR). In particular, isolated nucleic acid molecules are provided encoding human NAR protein. NAR polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NAR activity.Type: ApplicationFiled: March 1, 2002Publication date: December 12, 2002Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Stephen Ullrich, Kevin Baker
-
Publication number: 20020115112Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: August 15, 2001Publication date: August 22, 2002Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen, Stephen Ullrich
-
Publication number: 20020081647Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.Type: ApplicationFiled: February 19, 1999Publication date: June 27, 2002Applicant: Human Genome SciencesInventors: REINHARD EBNER, GUO-LIANG YU, STEVEN M. RUBEN, JUN ZHANG, STEPHEN ULLRICH, YIFAN ZHAI
-
Publication number: 20020064869Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily, Apoptosis Inducing Molecule II (AIM II). In particular, isolated nucleic acid molecules are provided encoding the human AIM II protein. AIM II polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, autoimmune disease, graft versus host disease, and to inhibit neoplasia, such as tumor cell growth.Type: ApplicationFiled: February 20, 1998Publication date: May 30, 2002Applicant: Human Genome Sciences, Inc.Inventors: REINHARD EBNER, GUO-LIANG YU, STEVEN M. RUBEN, STEPHEN ULLRICH
-
Publication number: 20020055147Abstract: The present invention relates to a novel CK&bgr;-13 protein which is a member of the chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK&bgr;-13 protein. CK&bgr;-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CKCK&bgr;-13 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: ApplicationFiled: July 20, 2001Publication date: May 9, 2002Inventors: Haodong Li, George Seibel, Stephen Ullrich, Francis W. Luscinskas